L-Ofloxacin
Critical Illness
Joel Thompson, PhDSmall moleculePhase 4 / ApprovedDormant
BB
67/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 89/ 100
Competitive context
10 Active assets in the Critical Illness cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VITAMIN D Massachusetts General Hospital | Phase 3 | BB |
GLUCOSE, ANHYDROUS Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Phase 4 | BB |
IMIPENEM University of Illinois at Chicago | Phase 4 | BB |
CILASTATIN University of Illinois at Chicago | Phase 4 | B |
Inulin Columbia University | Phase 2 | B |
View all 14 →
Same molecule, other indications
L-Ofloxacin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →